Leaving BNY Website

 

You are leaving the BNY Mellon's Depositary Receipts' Website.
Linked sites are not under the control of The Bank of New York Mellon Corporation or any of its subsidiaries or affiliates (together, the "Company") and the Company is not responsible for the content of any linked site or any link contained in a linked site. If you choose to link to a website not controlled by the Company, you do so entirely at your own risk and the Company makes no warranties, either express or implied, concerning the content of such site, including the accuracy, completeness, reliability or suitability thereof for any particular purpose, nor does the Company warrant that such site or content is free from any claims of copyright, trademark or other infringement of the rights of third parties or that such site or content is devoid of viruses or other contamination. The Company does not guarantee the authenticity of documents on the Internet. Links to other sites do not imply any endorsement of or responsibility for the opinions, ideas, products, information or services offered at such sites, or any representation regarding the content at such sites. The Company reserves the right to terminate any link at any time.

Do you wish to continue to the linked site on these terms?

Stay On Page
Leave Page

© 2025 The Bank of New York Mellon Corporation

Depositary Receipt business and services are conducted through The Bank of New York Mellon.

BNY - DR Legal Disclaimer
  

To learn more about DRs, please contact DRBrokerSolutions@bny.com.

 

The information and data provided herein are provided for general informational purposes only.  BNY does not warrant or guarantee the accuracy, timeliness or completeness of any such information or data.  BNY does not undertake any obligation to update or amend any information or data, and may change, update or amend any information or data at any time without prior notice.

 

BNY provides no advice, recommendation or endorsement with respect to any company or securities.  No information or data is intended to provide legal, tax, accounting, investment, financial, trading or other advice on any matter, and is not to be used as such.  We expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon any information or data, including market value loss on the sale or purchase of securities or other instruments or obligations.

 

Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.

 

BNY collects fees from DR holders pursuant to the terms and conditions of the DRs and any deposit agreement under which they are issued.  From time to time, BNY may make payments to an issuer to reimburse and/or share revenue from the fees collected from DR holders, or waive fees and expenses to an issuer for services provided, generally related to costs and expenses arising out of establishment and maintenance of the DR program.  BNY may pay a rebate to brokers in connection with unsponsored DR issuances; brokers may or may not disclose or pass back some or all of such rebate to the DR investor.  BNY may also use brokers, dealers or other service providers that are affiliates and that may earn or share fees and commissions.

 

BNY may execute DR foreign currency transactions itself or through its affiliates, or the Custodian or the underlying Company may execute foreign currency transactions and pay US dollars to BNY.  In those instances where it executes DR foreign currency transactions itself or through its affiliates, BNY acts as principal counterparty and not as agent, advisor, broker or fiduciary.  In such cases, BNY  has no obligation to obtain the most favorable exchange rate, makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate. BNY earns and retains revenue on its executed foreign currency transactions based on, among other things, the difference between the rate it assigns to the transaction and the rate that it pays and receives for purchases and sales of currencies when buying or selling foreign currency for its own account.  The methodology used by BNY to determine DR conversion rates is available to registered Owners upon request or can be accessed here.  In those instances where BNY's Custodian executes DR foreign currency transactions, the Custodian has no obligation to obtain the most favorable exchange rate or that the method by which the rate will be determined will be the most favorable rate, and BNY makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate.  In certain instances, BNY may receive dividends and other distributions from an issuer of securities underlying DRs in U.S. dollars rather than in a foreign currency.  In such cases, BNY will not engage in or be responsible for any foreign currency transactions and it makes no representation that the rate obtained by an issuer is a favorable rate and it will not be liable for any direct or indirect losses associated with the rate.

 

BNY is a global investments company dedicated to helping its clients manage and service their financial assets throughout the investment lifecycle.  BNY is the corporate brand of The Bank of New York Mellon Corporation (NYSE: BK).

 

BNY's name, brand and/or trademarks may not be used, copied or reproduced without the prior express written consent of BNY.

 

DEPOSITARY RECEIPTS ARE NOT INSURED BY THE FDIC OR ANY OTHER GOVERNMENT AGENCY, ARE NOT DEPOSITS OR OTHER OBLIGATIONS OF, AND ARE NOT GUARANTEED BY, BNY AND ARE SUBJECT TO INVESTMENT RISKS INCLUDING POSSIBLE LOSS OF PRINCIPAL AMOUNT INVESTED.

 

Please also see "Terms of Use."

ACCEPT

Please enable cookies in your browser if you wish to proceed.

Regulation S Disclaimer

 

Access To This Company Profile Is Restricted To Non-U.S. Persons Outside The United States Within The Meaning Of Regulation S Under The U.S. Securities Act Of 1933, As Amended (The "Securities Act").1

 

This company profile does not constitute an offer to sell or the solicitation of an offer to buy any securities in any jurisdiction or under any circumstances in which such offer or solicitation is unlawful.

 

Each person accessing this company profile, by so doing, will be deemed to have acknowledged that: (1) It is not a U.S. person (within the meaning of Regulation S under the Securities Act) and is located outside the U.S. (within the meaning of Regulation S under the Securities Act); and (2) Any securities described herein (A) have not been and will not be registered under the Securities Act or with any securities regulatory authority of any state or other jurisdiction and (B) may not be offered, sold, pledged or otherwise transferred except to persons outside the U.S. in accordance with Regulation S under the Securities Act pursuant to the terms of such securities.

 

If you agree with and accept the foregoing and the Terms of use governing this site, please select "Accept" below. Otherwise, press "Decline" to return to the previous page.

 

1 As defined in the Securities Act, the term "U.S Person" means: (1) any natural person resident in the United States; (2) any partnership or corporation organized or incorporated under the laws of the United States; (3) any estate of which any executor or administrator is a U.S. person; (4) any trust of which any trustee is a U.S. person; (5) any agency or branch of a foreign entity located in the United States; (6) any non-discretionary account or similar account (other than an estate or trust) held by a dealer or other fiduciary for the benefit or account of a U.S. person; (7) any discretionary account or similar account (other than an estate or trust) held by a dealer or other fiduciary organized, incorporated, or (if an individual) resident in the United States; and (8) any partnership or corporation if: (A) organized or incorporated under the laws of any foreign jurisdiction; and (B) formed by a U.S. person principally for the purpose of investing in securities not registered under the Securities Act, unless it is organized or incorporated, and owned, by accredited investors (as defined in Rule 501(a)) who are not natural persons, estates or trusts.

I Accept Decline

© 2024 The Bank of New York Mellon Corporation
Depositary Receipt business and services are conducted through The Bank of New York Mellon.

Back to Daily DR Market Summary

StreetAccount Summary - Europe Pre-Open: FTSE +0.1%, DAX +0.1%, CAC flat, IBEX (0.1%), MIB flat

Oct 06 ,2025

  • Synopsis

    • European equity markets are set to open mixed/little changed. Last week, European markets closed higher with the Stoxx Europe 600 up +2.87% and hitting new record highs. A pickup in Fed easing expectations also seemed to be a supportive factor in Europe with no incremental European central bank developments. There were also fresh record highs for the UK FTSE 100 last week.

    • This morning, crude strengthening after OPEC+ production hike came in less than speculated. Gold firming to fresh record high. Bitcoin also logged new ATH.

    • Focus on French politics. President Emmanuel Macron has unveiled a new cabinet led by Prime Minister Sébastien Lecornu. Roland Lescure is now Minister of Economy and Finance Lescure, a Macron loyalist with a leftist background, will need to negotiate the 2026 budget in a divided parliament. France24 writes that the new government under Lecornu already facing criticism.

    • Asian equities mixed Monday. Most of the focus is on Japan with Nikkei staging big rally on Takaichi's LDP leadership victory. Hong Kong weighed down by big tech. Australia flat. Mainland China, South Korea and Taiwan closed public holiday.

    • European macro data releases out today include Germany Sep construction PMI, Spain Aug industrial production, Eurozone Aug retail sales, Sep Sentix investor confidence, Switzerland Sep unemployment rate, UK Sep construction PMI, Denmark Aug manufacturing production. Also todayn, Germany, Russia and UK Sep new car registrations.

    • In central banks, ECB's Guindos speech at 9:30CET at Diario Expansión: XVI Encuentro Financiero, ECB Conf on Monetary Policy 2025: bridging science and practice (through Tue) and ECB's Lane giving a speech at 10:00CET. ECB's Lagarde delivers a speech at 19:00CET before EP Committee (livestream) and BOE's Bailey at 18:30BST at Scotland's Global Investment Summit (through Tue).

    • At the Conservative Party conf, Shadow Chancellor of the Exchequer Stride speech at 10:00BST.

    • This week sees Eurogroup meeting, French politicians continuing attempts to agree a budget for 2026, Germany Aug industrial production and Switzerland Sep unemployment rate as well as earnings/updates from the likes of Ferrexpo (FXPO.LN), LVMH Moet Hennessy Louis Vuitton (MC.FP), Mercedes-Benz Group (MBG.GR), OMV (OMV.AV), Repsol (REP.SM) and Tryg (TRYG.DC)

  • Politics/Macro/World News

    • Oil

      • OPEC+ to boost production by 137Kbpd in November

    • Gold and Bitcoin

      • Gold, Bitcoin Surge as 'Debasement Trade' Weighs on Currencies -- Bloomberg

    • UK

      • Reeves weighs up tax hike on banks that could raise £2bn -- i paper

      • Tories pledge £5,000 national insurance rebate for young homebuyers -- Times

      • Labour is coming for Middle England's property -- Telegraph

      • High-rise approval delays threaten UK building targets -- FT

    • France

      • New government under PM Sébastian Lecornu already facing criticism -- France24

      • Macron loyalist picked to fix budget mess in new French government -- Reuters

  • Top company news

    • Earnings/updates

      • SK.FP (SEB) -- Q3 sales expected to show a slight organic decline, resulting in lower results, below forecasts; lowers FY Operating Result from Activity guidance to €550-600M vs prior guidance €700-750M

      • HNR1.GR (Hannover Re) -- reports dividend to be raised to around 55% of IFRS Group net income

      • AKRBP.NO (Aker BP) -- reports Q3 net production mboepd 414.0K vs vs quarter-ago 415.0K

      • RDC.GR (Redcare Pharmacy) -- reports preliminary Q3 revenue €719M vs FactSet €715.2M [3 est, €712-718M], reaffirms FY guidance

      • SK.FP (SEB) -- Q3 sales expected to show a slight organic decline, resulting in lower results, below forecasts; lowers FY Operating Result from Activity guidance to €550-600M vs prior guidance €700-750M

      • LSG.NO (Lerøy Seafood Group) -- Q3 trading update: total harvest volume of salmon and trout (GWT) 59,100 vs year-ago 51,400

      • Also reporting today

        • Earnings:

          • UK: Beeks Financial Cloud Group (BKS.LN)

        • Trading Update:

          • France: LDC (LOUP.FP)

          • Southern Europe: Repsol (REP.SM)

          • UK: Ferrexpo (FXPO.LN)

        • Traffic: Norwegian Air Shuttle (NAS.NO), Icelandair Group (ICEAIR.IR)

        • CMD/Events: Compagnie de Saint-Gobain (SGO.FP)

    • M&A

      • EXAE.GA (Hellenic Exchanges-Athens Stock Exchange) -- Euronext launches offer for Hellenic Exchanges-Athens Stock Exchange

      • BBVA.SM (BBVA) -- BBVA has 8 billion euros to fund mandatory bid for Sabadell if needed, CEO says

      • BNP.FP (BNP Paribas) -- completes acquisition of HSBC private banking activities in Germany

      • FAGR.BB (Fagron) -- receives Brazilian antitrust clearance for Purifarma and Injeplast acquisitions

      • MGN.NO (Magnora) -- acquires majority stake in Storespeed AS; price undisclosed

      • ISB.IR (Íslandsbanki) -- and Skagi boards approve initiation of formal merger discussions

      • New Zealand government plans to increase LNG supply could impact sale process for Igneo's Clarus - The Australian

    • Healthcare

      • ROG.SW (Roche Holding) -- Roche receives CE Mark for AI-based Kidney Klinrisk Algorithm and launches new comprehensive chronic kidney disease (CKD) algorithm panel

      • ETNB (89bio, Inc.) -- holder Adage Capital, Robert Atchinson and Phillip Gross, et al discloses stake of 6.1% - 13D

      • ABVX.FP (Abivax) -- reports results from first of two late-breaking presentations at UEG Meeting

      • NYXH.BB (Nyxoah) -- Announces First US Commercial Patients Implanted with Genio System

      • PHARM.NA (Pharming Group) -- FDA grants orphan drug designation to leniolisib (Joenja) for common variable immunodeficiency

      • TNG.FP (Transgene) -- to present new immunological data from Phase I trial of TG4050 at SITC 2025

    • Other

      • EDEN.FP (Edenred) -- announces share buyback mandate

      • OMV.AV (OMV) -- amends dividend policy starting with financial year 2026, first payout in 2027

      • SUNN.SW (Sunrise Communications) -- confirms termination of sponsored Class A ADS program to become effective as of 13-Nov-25

      • ANIM.IM (Anima Holding SpA) -- announces resignation of CEO Alessandro Melzi d'Eril, effective immeditaely

  • Key rating changes

    • Upgrades

      • AI.FP (Air Liquide) -- to hold from reduce at Kepler Cheuvreux

      • AZA.SS (Avanza Bank Holding) -- to hold from reduce at Kepler Cheuvreux

      • EPI.A.SS (Epiroc) -- to buy from hold at Pareto

    • Downgrades

      • SAND.SS (Sandvik) -- to hold from buy at Pareto

      • MNDI.LN (Mondi) -- to neutral from overweight at JPMorgan

      • GET.FP (Getlink) -- to neutral from buy at UBS

      • QQ.LN (QinetiQ Group) -- to hold from buy at Kepler Cheuvreux

      • ASHM.LN (Ashmore Group) -- to underweight from equal weight at Barclays

      • SFL.IM (Safilo Group) -- to hold from buy at Kepler Cheuvreux

  • Data

    • Nikkei +5.04% to 48075.60

    • Hang Seng (0.72%) to 26944.79

    • Shanghai Composite +0.00% to 3882.78

    • S&P futures +17.8 vs prior close of 6764.0

    • €-$ (0.0014) or (0.12%) to 1.1715

    • $-¥ +0.96 or +0.64% to 150.29

    • €-¥ +3.08 or +1.78% to 176.05

This information and data is provided for general informational purposes only. The Bank of New York Mellon and our information suppliers do not warrant or guarantee the accuracy, timeliness or completeness of this information or data. We provide no advice nor recommendation or endorsement with respect to any company or securities. We do not undertake any obligation to update or amend this information or data. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.
Please refer to "Terms Of Use".

DEPOSITARY RECEIPTS:
NOT FDIC, STATE OR FEDERAL AGENCY INSURED
MAY LOSE VALUE
NO BANK, STATE OR FEDERAL AGENCY GUARANTEE